Telomir Pharmaceuticals, Inc. (TELO) Stock Statistics & Valuation Metrics

Telomir Pharmaceuticals, Inc. has a market cap or net worth of $43.32M. The enterprise value is $36.03M.

Telomir Pharmaceuticals, Inc. has 34,380,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telomir Pharmaceuticals, Inc.’s return on equity (ROE) is -1.76 and return on invested capital (ROIC) is -178.22%.

The current PE Ratio of Telomir Pharmaceuticals, Inc. is ―. Telomir Pharmaceuticals, Inc.’s PEG ratio is 0.10.

In the last 12 months, Telomir Pharmaceuticals, Inc. had revenue of 0.00 and earned -10.41M in profits. Earnings per share was -0.33.

In the last 12 months, operating cash flow was -3.69M and capital expenditures 6.00, giving a free cash flow of -3.69M billion.

Telomir Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Telomir Pharmaceuticals, Inc. upcoming earnings date is ―, ―.

Telomir Pharmaceuticals, Inc. as a current ratio of 5.14, with Debt / Equity ratio of 0.00%

In the past 12 months, Telomir Pharmaceuticals, Inc. has paid 0.00 in taxes.

Telomir Pharmaceuticals, Inc. EV to EBITDA ratio is -3.30, with an EV/FCF ratio of -9.44.

Telomir Pharmaceuticals, Inc. has $7.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of $7.29M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Telomir Pharmaceuticals, Inc. is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy